S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
LON:SALV

SalvaRx Group Share Forecast, Price & News

GBX 4.50
0.00 (0.00 %)
(As of 12/19/2019)
Add
Compare
Today's Range
4.50
Now: GBX 4.50
7.90
50-Day Range
4.50
MA: GBX 4.50
4.50
52-Week Range
4.50
Now: GBX 4.50
7.90
Volume50,758 shs
Average Volume50,758 shs
Market Capitalization£1.65 million
P/E Ratio0.03
Dividend YieldN/A
BetaN/A
SalvaRx Group plc discovers and develops immune-oncology drugs. The company is based in Ramsey, Isle of Man.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1624-811611
Employees2
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£64.50 million
Cash FlowGBX 1.29 per share
Book ValueGBX 15.40 per share

Profitability

Miscellaneous

Market Cap£1.65 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.94 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
GBX 4.50
0.00 (0.00 %)
(As of 12/19/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive SALV News and Ratings via Email

Sign-up to receive the latest news and ratings for SALV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











SalvaRx Group (LON:SALV) Frequently Asked Questions

What stocks does MarketBeat like better than SalvaRx Group?

Wall Street analysts have given SalvaRx Group a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but SalvaRx Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has SalvaRx Group's stock been impacted by COVID-19 (Coronavirus)?

SalvaRx Group's stock was trading at GBX 4.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SALV shares have increased by 0.0% and is now trading at GBX 4.50.
View which stocks have been most impacted by COVID-19
.

Who are SalvaRx Group's key executives?

SalvaRx Group's management team includes the following people:
  • Mr. Denham Hervey Newall Eke, CFO & Director (Age 67)

Who are some of SalvaRx Group's key competitors?

What other stocks do shareholders of SalvaRx Group own?

What is SalvaRx Group's stock symbol?

SalvaRx Group trades on the London Stock Exchange (LON) under the ticker symbol "SALV."

How do I buy shares of SalvaRx Group?

Shares of SALV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is SalvaRx Group's stock price today?

One share of SALV stock can currently be purchased for approximately GBX 4.50.

How much money does SalvaRx Group make?

SalvaRx Group has a market capitalization of £1.65 million and generates £64.50 million in revenue each year.

How many employees does SalvaRx Group have?

SalvaRx Group employs 2 workers across the globe.

What is SalvaRx Group's official website?

The official website for SalvaRx Group is www.salvarx.io.

Where are SalvaRx Group's headquarters?

SalvaRx Group is headquartered at Commerce House, 1 Bowring Road, RAMSEY, RAMSAY, IM8 2LQ, Isle of Man.

How can I contact SalvaRx Group?

SalvaRx Group's mailing address is Commerce House, 1 Bowring Road, RAMSEY, RAMSAY, IM8 2LQ, Isle of Man. The company can be reached via phone at +44-1624-811611.


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.